Unity Biotechnology (NASDAQ:UBX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Unity Biotechnology (NASDAQ:UBX) issued its earnings results on Monday. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02, Zacks reports.

Unity Biotechnology Trading Down 0.8 %

Shares of UBX traded down $0.01 on Wednesday, reaching $1.20. 15,800 shares of the company’s stock traded hands, compared to its average volume of 62,655. The stock’s 50 day simple moving average is $1.44 and its two-hundred day simple moving average is $1.47. The stock has a market cap of $20.22 million, a PE ratio of -0.92 and a beta of 0.83. Unity Biotechnology has a 52-week low of $1.12 and a 52-week high of $2.26.

Analysts Set New Price Targets

A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Unity Biotechnology in a report on Thursday, August 8th. Rodman & Renshaw initiated coverage on Unity Biotechnology in a research note on Thursday, August 22nd. They set a “buy” rating and a $8.00 price objective on the stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.